Stryker
This article was originally published in The Gray Sheet
Executive Summary
Imminent spin-off of the orthopedic firm's competitor Zimmer from parent company Bristol Myers Squibb will help solidify pricing in the orthopedic market, the firm maintains. As a public entity accountable to investors, Zimmer would be less likely to implement discount pricing, a strategy used when it was part of the larger BMS pharmaceutical firm, Stryker says